Search documents
New York City Sues to Ban ‘Unlawful’ Empower Ridehail App
Insurance Journal· 2026-03-31 05:00
New York City sued ridehail app Empower and founder Joshua Sear, claiming the company has been operating unlawfully without a license the past few years even as the service gained popularity by offering cheap fares to customers.Empower has violated local laws by failing to apply for relevant licenses since it began operating in the city in 2022, New York said in a lawsuit filed Friday in state court. The city said it seeks to permanently ban the “unlawful” ridehail service. “New York City will not tolerate ...
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
Globenewswire· 2026-03-31 05:00
Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at lea ...
Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease
Globenewswire· 2026-03-31 05:00
Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at lea ...
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
Globenewswire· 2026-03-31 05:00
BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases.BioVersys joins forces with Hackensack Meridian Health (HMH) and their Center for Discovery and Innovation (CDI) to advance ansamycin antimicrobial candidates through an exclusive collaboration and license agreement.HMH is a leading US not-for-profit health care network, and the largest in New Jersey. NTMs are u ...
Fed hike could raise recession risk: David Rosenberg
Youtube· 2026-03-31 04:58
You know, we mentioned a couple of minutes ago that Fed Jer Powell is taking a very sort of sanguin view of what's going on, saying, "Look, inflation, the oil shock, the Middle East war, etc., it's not going to be that much of a problem for the US. So, we'll sort of do nothing right now and uh still continue to focus on the labor market." I is that the right thing to do to be doing. >> Uh well, I I think uh 100% that it is. At least he didn't use the word transitory.Uh but uh I think that uh he's he's quite ...
江苏宁沪高速公路发布2025年度业绩,归母净利润约45.94亿元,同比下降约7.13%
Zhi Tong Cai Jing· 2026-03-31 04:58
2025年,公司以巩固路桥主业优势为根基,以深化数智融合创新为引擎,以加速绿色低碳转型为路径, 以培育可持续增长动能为目标,推动各项业务深度协同,迈入能级提升、质效双优的新阶段。 宁沪高速 江苏宁沪高速 分时图 日K线 公路周K线 月K线 12.05 0.08 0.67% 1.67% 1.09% 0.58% 0.00% 0.58% 1.09% 1.67% 11.77 11.84 11.90 11.97 12.04 12.10 12.17 09:30 10:30 11:30/13:00 14:00 15:00 600 23万 46万 69万 江苏宁沪高速(600377)公路(00177)发布2025年年度业绩,营业收入约202.89亿元(人民币,下同),同 比下降约12.54%;归属于上市公司股东的净利润约45.94亿元,同比下降约7.13%;每股收益0.9119元,拟 派发现金股息每股0.49元(含税)。 本报告期,集团实现通行费收入约95.55亿元,同比增长约0.29%,通行费收入占集团总营业收入约 47.10%,剔除建造收入后,占比约78.75%。其中,沪宁高速日均通行费收入约1508.2万元,同比增长约 ...
渣打集团3月27日斥资1485.4万英镑回购96.4万股
Zhi Tong Cai Jing· 2026-03-31 04:58
渣打集团 渣打集团(02888)发布公告,于2026年3月27日斥资1485.4万英镑回购96.4万股。 分时图 日K线 周K线 月K线 156.70 -2.50 -1.57% 1.57% 1.05% 0.52% 0.00% 0.52% 1.05% 1.57% 156.70 157.53 158.37 159.20 160.03 160.87 161.70 09:30 10:30 12:00/13:00 14:00 16:10 0 2万 4万 7万 ...
Trump's sensitivity to markets gives Iran leverage: BCA Research
Youtube· 2026-03-31 04:58
Right now the main phase is just trying to prevent the ability of Iran to you know externally attack using missiles and drones and the drones themselves are going to be an ongoing nuisance. But if they can provide enough clearance of form that they can then start escorting vessels then you'll start to see more shipping move and then markets will start to be uh a little bit more encouraged. And that's critical here because if the market loses confidence and the floor drops out from this, then the president h ...
'Show me the barrels': Bob McNally says Trump is failing to reassure oil markets
Youtube· 2026-03-31 04:58
The president has been very successful until recently as you just noted uh at verbally intervening to dampen crude oil prices. And it's not just that the president has made reassuring comments and so forth. But you got to remember going into this, no one expected it.No one expected anyone would be allowed to shut down Hormuz traffic for two or three days. Rapidan did. We we had analyzed it in detail back in June.So, we weren't surprised, but most folks were. And they expected it to end soon. It's like a nig ...
Design, disruption, and drama: Apple's most defining controversies
ETBrandEquity.com· 2026-03-31 04:57
It has also been at the centre of legal battles and ongoing scrutiny over the control it exerts through its App Store ecosystem. At the same time, Apple has taken a firm and often contentious stance on user privacy, most notably in its refusal to compromise encryption even under government pressure. Yet, despite these challenges, Apple remains one of the world's most powerful and influential brands-shaping consumer behaviour, culture and technology-while continually navigating the complex realities behind i ...